Clinical value of serum miR-103b levels in patients with atherosclerotic cardiovascular disease
Objective To investigate the expression and clinical value of miR-103b in serum of the patients with atherosclerosis cardio-vascular disease(ASCVD).Methods The serum samples were collected from 80 ASCVD patients who were diagnosed in the Depart-ment of Cardiology,General Hospital of Eastern Theater Command from January 2021 to November 2022,and 80 serum samples of healthy controls were simultaneously collected.Quantitative real-time polymerase chain reaction(qRT-PCR)was used to detect the ex-pression level of miR-103b in serum.ROC curve and Spearman correlation analysis were used to evaluate the predictive value of serum miR-103b for ASCVD.Results Compared to the control group[0.000 2(0.000 08,0.000 3)],the expression level of miR-103b in the serum of ASCVD group[0.001 7(0.000 8,0.003 3)]was significantly up-regulated(U=1 069,P＜0.001).Correlation analysis showed that miR-103b was positively correlated with cardiac troponin I(cTnI)(r=0.322,P＜0.05),cTnT(r=0.298,P＜0.05),cre-atine kinase-MB(CK-MB)(r=0.393,P＜0.05),cholesterol(r=0.290,P＜0.001),low density lipoprotein cholesterol(r=0.268,P＜0.001),and was negatively correlated with high density lipoprotein cholesterol(r=-0.313,P＜0.001).The ROC curve analysis showed that the area under the ROC curve(AUCROC)of serum miR-103b levels distinguishing ASCVD patients and healthy controls was 0.854(95%CI:0.791-0.917)with sensitivity of 73.26%and specificity of 83.92%.Conclusion The expression of miR-103b in serum of the patients with ASCVD is significantly up-regulated compared with healthy control.The level of miR-103b could be used as a potential molecular biomarker for auxiliary diagnosis of ASCVD.
NETL
NSTL
万方数据
维普
